Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502

Eyal C Attar, M.D., Kathleen A. Donohue, M.A., Philip C. Amrein, MD, Martha Wadleigh, MD, Daniel J DeAngelo, MD, PhD, Jonathan E Kolitz, MD, Bayard L. Powell, MD, Peter M Voorhees, M.D., Eunice S. Wang, MD, William Blum, MD, Allison Booth, Richard M Stone, M.D., Barry K Moser, Ph.D., Richard Larson, M.D.

Blood (2010) 116 (21): 331.

https://doi.org/10.1182/blood.V116.21.331.331

Published: 2010

Journal Articles

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101.

Thomas S Lin, MD, PhD, Kathleen A Donohue, John C. Byrd, MD, Margaret S Lucas, Eva Hoke, Elizabeth M Bengtson, MD, James N Atkins, MD, Brian K Link, MD, Kanti R Rai, MD, Richard A Larson, MD

Blood (2009) 114 (22): 210.

https://doi.org/10.1182/blood.V114.22.210.210

Published: 2009

Journal Articles

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101.

Thomas S. Lin, MD, PhD, Kathleen A. Donohue, MA, Margaret S. Lucas, BS, PA, John C. Byrd, MD, Elizabeth M. Bengtson, MD, Bercedis L. Peterson, PhD, Richard A. Larson, MD

Blood (2007) 110 (11): 755.

https://doi.org/10.1182/blood.V110.11.755.755

Published: 2007

Journal Articles

Autologous Stem Cell Transplantation (SCT) Following Sequential Chemotherapy and Imatinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) — CALGB Study 10001.

Meir Wetzler, MD, Wendy Stock, MD, Kathleen A. Donohue, MS, Kouros Owzar, PhD, Dorie A. Sher, MS, Eva E. Hoke, BS, John M. McCarty, MD, William G. Blum, MD, Bayard L. Powell, MD, Clara D. Bloomfield, MD, Charles A. Linker, MD, Richard A. Larson, MD

Blood (2007) 110 (11): 2869.

https://doi.org/10.1182/blood.V110.11.2869.2869

Published: 2007

Journal Articles

T Cell Activation by t(9;22) Acute Lymphoblastic Leukemia-Derived Dendritic-Like Cells Is Associated with Increased Expression of Antigen Processing Machinery Components.

Jonathan A. Claus, Michael A. Brady, BS, Jaewoo Lee, PhD, Kathleen A. Donohue, MS, Soldano Ferrone, MD, PhD, Meir Wetzler, MD

Blood (2004) 104 (11): 4301.

https://doi.org/10.1182/blood.V104.11.4301.4301

Published: 2004

Journal Articles

Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival

Mustafa Benekli, Zheng Xia, Kathleen A. Donohue, Laurie A. Ford, Lynda A. Pixley, Maria R. Baer, Heinz Baumann, Meir Wetzler

Blood (2002) 99 (1): 252–257.

https://doi.org/10.1182/blood.V99.1.252

Published: 2002

NARROW

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101.

Autologous Stem Cell Transplantation (SCT) Following Sequential Chemotherapy and Imatinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) — CALGB Study 10001.

T Cell Activation by t(9;22) Acute Lymphoblastic Leukemia-Derived Dendritic-Like Cells Is Associated with Increased Expression of Antigen Processing Machinery Components.

Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival

Email alerts

ASH Publications

American Society of Hematology

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101.

Autologous Stem Cell Transplantation (SCT) Following Sequential Chemotherapy and Imatinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) — CALGB Study 10001.

T Cell Activation by t(9;22) Acute Lymphoblastic Leukemia-Derived Dendritic-Like Cells Is Associated with Increased Expression of Antigen Processing Machinery Components.

Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only